IP Library Patent Application 13412747
Patent Application
App. No. 13/412,747

Substituted Imidazole Derivatives, Compositions, and Methods of Use as PTPase Inhibitors

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/412,747
Abstract

The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.

Claims (10)

1 . 5-(3-{4-(2,4-Dichloro-phenyl)-2-[3′-(3,3-dimethyl-butoxy)-biphenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide or a pharmaceutically acceptable salt thereof.

2 . The compound of claim 1 , wherein the pharmaceutically acceptable salt is a sodium salt or a potassium salt.

3 . 5-(3-{4-(2,4-Dichloro-phenyl)-2-[3′-(3,3-dimethyl-butoxy)-biphenyl-4-ylmethyl]-imidazol-1-yl}-phenyl)-1,2,5-thiadiazolidine-3-one-1,1-dioxide.

4 . A pharmaceutical composition comprising the compound of claim 1 , and a pharmaceutically acceptable carrier, diluents, excipient, or a mixture thereof.

5 . A pharmaceutical composition comprising the pharmaceutically acceptable salt of claim 1 , and a pharmaceutically acceptable carrier, diluents, excipient, or a mixture thereof.

6 . 5-{3-[2-(4′-Cyclohexylmethoxy-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide or a pharmaceutically acceptable salt thereof.

7 . The compound of claim 6 , wherein the pharmaceutically acceptable salt is a sodium salt or a potassium salt.

8 . 5-{3-[2-(4′-Cyclohexylmethoxy-biphenyl-4-ylmethyl)-4-(2,4-dichloro-phenyl)-imidazol-1-yl]-phenyl}-1,2,5-thiadiazolidine-3-one-1,1-dioxide.

9 . A pharmaceutical composition comprising the compound of claim 6 , and a pharmaceutically acceptable carrier, diluents, excipient, or a mixture thereof.

10 . A pharmaceutical composition comprising the pharmaceutically acceptable salt of claim 6 , and a pharmaceutically acceptable carrier, diluents, excipient, or a mixture thereof.

Assignments (3)
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS FOR REEL/FRAME 030982/0803 Recorded Apr 7, 2014
From: M&F TTP HOLDINGS LLC
To: TRANSTECH PHARMA, LLC
Reel/Frame 032621/0860 →
SECURITY AGREEMENT Recorded Aug 9, 2013
From: TRANSTECH PHARMA, INC.
To: M&F TTP HOLDINGS LLC C/O MACANDREWS & FORBES HOLDINGS INC.
Reel/Frame 030982/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2012
From: MJALLI, ADNAN M.M.; POLISETTI, DHARMA R.; SUBRAMANIAN, GOVINDAN; QUADA, JAMES C.; YARRAGUNTA, RAVINDRA R.; ANDREWS, ROBERT C.; XIE, RONYUAN
To: TRANSTECH PHARMA, INC.
Reel/Frame 027868/0083 →